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Poster Session I S251Neutropenia-associated bacteremia has been reported to occur in
20-60% of patients following myeloablative HSCT. Mortality up to
40% may occur with gram negative organisms. To address these
concerns, in 1998 our program revised supportive care guidelines
to include bacterial prophylaxis with meropenem for patients under-
going myeloablative HSCT. Meropenem was started when the
WBC fell below 1000/mcl and continued until the ANC
was$ 500/mcl. This report analyzes outcomes for patients treated
with this strategy.
Between 9/1/1998 and 9/1/2008, 370 transplants were performed.
Of these, 134 who underwent outpatient autologous HSCT received
different infection prophylaxis and were excluded from this analysis.
An additional 24 patients were excluded for other reasons (active bac-
terial infection prior to leukopenia5 15; never received
meropenem5 9). Thus, 212 transplants in 201 patients were evalu-
able for this retrospective analysis (auto5 67 HSCT/65 patients;
allo5 145 HSCT/136 patients). Evaluable patients had a median
of 19 days of ANC\500/mcl (range, 3 – 79 days) between the start
of myeloablation and subsequent myeloid engraftment. The study
group experienced 4409 total days of neutropenic risk for bacteremia.
The outlined strategy was successful in preventing a first bacter-
emic episode in 88% of evaluable transplants (94%, auto; 86%,
allo). Conversely, prophylaxis failed to prevent an initial neutropenic
bacteremia in 12% of transplants (n5 25) overall (6%, auto; 14%,
allo). Meropenem was started at a median of Day -2 (range, Day
-16 to Day +9) and continued for a median of 21 days (range, 1 –
81 days). Initial positive blood cultures occurred at a median of
Day +6 post-HSCT after a median of 10 days of meropenem. Pro-
phylaxis failures were primarily with organisms innately resistant
to meropenem (Coag Negative Staphylococci5 16; Enterococcus5 2;
Stenotrophomonas5 3; other5 4). No instances of meropenem-in-
duced resistant organisms were identified in failures of primary pro-
phylaxis. Initial bacteremias contributed to the deaths of 3 patients,
all post allogeneic HSCT. Thus, neutropenic bacteremias were the
cause of death in 1.4% of all transplants (3/212); none in autologous
HSCT (0/67), 2% in allogeneic HSCT (3/145).
In summary, these results suggest that prophylactic use of merope-
nem may be an effective strategy for reducing the risk of bacteremia
and septic death in children, adolescents and young adults undergo-
ing myeloablative autologous or allogeneic HSCT.250
PERFORMANCE CHARACTERISTICS OF GALACTOMANNAN ENZYME IM-
MUNOASSAY IN PEDIATRIC ALLOGENEIC HSCT RECIPIENTS
Lewis, J.A.1, Ragucci, D.P.2, Nista, E.J.1, Hudspeth, M.P.1 1 Medical
University of South Carolina, Charleston, SC; 2 Medical University of
South Carolina, Charleston, SC
Invasive fungal infections (IFI) are a major cause of morbidity and
mortality in allogeneic hematopoietic stem cell transplant (HSCT)
recipients. Galactomannan enzyme immunoassay (EIA) surveillance
testing offers the potential for earlier diagnosis and initiation of ther-
apy. The majority of data regarding galactomannan EIA testing after
HSCT is reported in adult patients. Approval was obtained from the
Institutional Review Board at our institution for a retrospective chart
review of allogeneic HSCT patients from July 1, 2007 July 30, 2009.
Galactomannan EIA testing was obtained 314 times among the 27
patients for an average of 11.6 tests per patient. IFI was defined as ei-
ther proven or probable disease based on the European Organization
for Research and Treatment of Cancer/Mycosis Study Group guide-
lines. Among the 27 patients, there were no cases of proven disease, 1
case of probable disease, and 8 cases of possible disease. There were 5
positive isolated tests without evidence of disease in 4 different pa-
tients. The galactomannan EIA had a sensitivity of 1.00, specificity
of 0.5, positive predictive value (PPV) of 0.07, and negative predic-
tive value (NPV) of 1. Of the 8 patients with possible IFI, 4 had
chronic GVHD. The galactomannan EIA values among the possible
IFI cases ranged from 0.59-7.69. The one probable IFI case also had
chronic GVHD and galactomannan EIA values ranged from 0.5-
1.12. Among the 4 patients with positive tests without evidence of
disease, the galactomannan EIA values ranged from 0.56- 8.57.
None of these patients had identified risk factors for false-positivetests such as administration of beta-lactam antibiotics or gastrointes-
tinal GVHD. Among our patients, the incidence of IFI was 3.7%,
well under the typically reported incidence of 7-10% in allogeneic
HSCT recipients. A decreased incidence and consequently de-
creased prevalence of IFI in our patients likely explains the decreased
PPV but preserved NPV of galactomannan EIA screening in our pe-
diatric allogeneic HSCT patients. HSCT centers should be aware of
the impact of their local incidence of IFI on the performance charac-
teristics of galactomannan EIA.
Table 1. Diagnostic Validity of Galactomannan EIA testing
Positive IFI Negative IFIPositive Galactomannan EIA 1 13
Negative Galactomannan EIA 0 13Sensitivity5 1/15 1.0 Specificity5 13/265 0.5 Positive Predictive Val-
ue5 1/145 0.07 Negative Predictive Value5 13/135 1.0251
EVALUATION OF THE CLINICAL OUTCOMES OF PEDIATRIC PATIENTS
WITH PERIPHERAL EOSINOPHILIA FOLLOWING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
O’Hear, C.1, Eckstein, O.1, Lehmann, L.2, Duncan, C.2 1 Children’s Hos-
pital, Boston, MA; 2 Dana Farber Cancer Institute, Boston, MA
Eosinophilia has been proposed to have prognostic significance
for survival and for the development of graft-versus-host disease
(GVHD) in adult patients following hematopoietic stem cell trans-
plantation (HSCT). However, the prognostic significance of post-
transplant eosinophilia in regards to GVHD and overall survival
has not been well-studied in the pediatric population. We performed
a retrospective analysis of the clinical impact of eosinophilia in 84 pe-
diatric patients following allogeneic HSCT performed for malignant
and non-malignant diseases. The clinical outcomes of patients with
eosinophilia were compared to patients transplanted during the
same time period that did not have eosinophilia. Eosinophilia was
defined as either an absolute number of greater than 0.5  10^9/L
or an eosinophil percentage greater than 4 in the peripheral blood
on at least two consecutive measurements. Seventy-one patients de-
veloped eosinophilia at a median 155 days from transplant. Forty-
two percent of patients had absolute eosinophilia and eighty-three
percent of patients had an elevated eosinophil percentage. The over-
all survival of all patients was sixty-nine percent. Thirty-six percent
of patients developed chronic GVHD and thirty percent developed
acute GVHD. Eosinophilia was not significantly associated with in-
creased mortality (odds ratio 2.7, 95% confidence interval 0.8-8.5);
acute GVHD (OR 2.6, CI 0.5-12.5), or chronic GVHD (OR 2.1,
CI 0.4-10.2). In this pediatric population, post-HSCT eosinophilia
does not have prognostic significance for mortality or the presence
or development of GVHD. Larger pediatric studies are needed to
further evaluate the impact of eosinophilia in children.252
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH
FANCONI ANEMIA: WHAT ARE THE NUTRITIONAL CONSENQUENCES?
Campos, D.J., Koerich, A., Biagini, G.L., Bonfim, C.M.S., Zanis Neto, J.,
Boguszewski, C.L., Borba, V.Z.C. Federal University of Parana, Curitiba,
PR, Brazil
Introduction: Fanconi Anemia (FA) is a rare disease characterized
by bone marrow failure, congenital abnormalities and a predisposi-
tion to cancer. Patients (pts) with FA usually have low birth weight,
short stature and fatigue. Hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pts that develop hematological
abnormalities but it increases energy expenditure due to complica-
tions related to this procedure and decreases oral ingestion by the
presence of gastrointestinal symptoms.
Objective: Evaluate the changes in nutritional status, in food intake,
in bone mineral density (BMD) and in vitamin D serum levels in
S252 Poster Session Ichildren and adolescents with FA who underwent allogeneic HSCT
in a single institution.
Methodology: Pts were evaluated before and 180 days after HSCT.
We evaluated the lean mass (LM) by electrical bioimpedance, nutri-
tional status by anthropometric measurements, the food intake by
a 24 hours recall, the BMD by DXA (HOLOGIC-1000) and the se-
rum 25-hydroxyvitamin D (25-OHD).
Results: Between 08/2006 and 09/2008, twenty-four patients
were included in the study. Seven pts (29%) died before
D + 180 and were excluded from this analysis. 17 pts were able
to complete this survey. The median age at admission to the
BMT Unit was 8,5ys (5-16ys), 9 pts (53%) were female and 10
pts (59%) received TCTH from unrelated donors. Most patients
(88%) developed mucositis while 7 pts (41%) developed acute or
chronic graft-versus-host disease (GVHD). Prior to HSCT, 6 pa-
tients (35%) had moderate to severe malnutrition, 10 (59%) pre-
sented short stature, 2 (12%) had low BMD for age and 11
(65%) had low vitamin D serum levels. The energy consumption
was inadequate in 6 (35%) patients and no patient had inade-
quate protein intake. At 180 days post-HSCT, six (35%) patients
had inadequate caloric intake, 1 (5%) patient had inadequate pro-
tein intake and 13 patients (76%) had low vitamin D serum
levels. A severe weight loss (greater than 5%) occurred in 6
(35%) pts, the LM decreased in 8 (47%) patients and 10
(69%) had a reduction in BMD.
Conclusion: The prevalence of weight, LM and BMD reduction
was high after six months of HSCT. The vitamin D serum levels
were low before and after HSCT. Pre-transplant nutritional care
and nutritional status monitoring of these patients are essential to
ensure proper growth and development, reducing at the most as pos-
sible the nutritional deficit during treatment.253
LONG-TERM IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION ON THE NUTRITIONAL STATUS OF INFANTS
Koerich, A., Campos, D.J., Jung, R.M., Ordonez, A.M., Fortier, S.C.,
Koliski, A., Zanis Neto, J., Bonfim, C.M.S. Federal University of Parana,
Curitiba, PR, Brazil
Introduction:During the first 2 years of life the adequate nutritional
status (NS) maintenance is crucial to ensure full growth and develop-
ment.
Objectives:Evaluate changes in NS of infants undergoing HSCT in
Curitiba-Brazil during hospitalization and the long-term impact in
the NS. Analyze the nutritional therapy applied and implications
of this intervention to the patient’s outcome.
Methods: Data was collected retrospectively from medical records
considering the anthropometry at the time of hospitalization and
last outpatient visit. All pts younger than 2 years-old, transplanted
between 12/1990 and 11/2007 were included.
Results: 53pts were included, 38 (72%) were male, age was
13.56 6.2 months, 43 pts (81%) had non malignant diseases,
29 (55%) received HSCT from unrelated donors. At hospitaliza-
tion 17 pts (32%) showed mild to moderate malnutrition and 8
pts (15%) severe malnutrition. At hospital discharge, 21 pts
(40%) showed mild to moderate malnutrition and 9 pts (17%)
severe malnutrition. During hospitalization 6 pts (11%) lost 5-
10% of body weight and 3 pts (6%) lost over 10%. There was
no relationship between the baseline NS and survival, and be-
tween pathology, length of hospital stay and weight loss. 14
pts (26%) received tube feeding (TF) for 12.76 11.5 days, to
supply an average of 30.4 kcal/kg/day and 0.9 g protein/kg/day.
22 (42%) patients received parenteral nutrition (PN) for
15.76 6.1 days to supply 49.8 kcal/kg/day and 1.5 g protein/kg/
day. There was no statistical difference in the incidence of vom-
iting, diarrhea and hyperglycemia among patients who received
TF, PN or exclusively oral feeding. 30 pts survived at least
one year with a median follow up of 25406 1448 days. Age
was 6.46 3.9 years at the latest evaluation, 11 pts (33%) devel-
oped GVHD. Regarding the current NS, 19 pts (58%) had short
stature, 13 pts (39%) showed mild to moderate malnutrition and
4 pts (12%) had severe malnutrition. Analyzing the height/agecurve, 15 pts (45%) did not reach an ascendant growth curve af-
ter HSCT and 14 pts (42%) did not reach an ascendant weight/
age curve.
Conclusion:We observed a high prevalence of malnutrition prior to
HSCT and many pts persisted with long term deficits in height and
weight after transplant. The use of TF did not lead to increased gas-
trointestinal complications and could be used in order to prevent
weight loss during HSCT and diminish nutritional long term com-
plications.254
TWO YEARS WORKING: EXPERIENCE OF THE FIRST EXCLUSIVELY PEDI-
ATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM IN COLOM-
BIA, SOUTHAMERICA
Estupinan, M., Chaparro, M. Fundacion Hospital de la Misericordia,
Bogota, Colombia
We describe the experience after two years working at the first ex-
clusively Pediatric Hematopoietic Stem cell Facility in Bogota, Co-
lombia. 26 hematopoietic stem cell transplants (HSCT) have been
done in our program. 15 (57%) allogeneic and 11(43%) autologous
HSCTs. Between allogeneic transplants all donors have been match
related donors, 53% of allogeneic transplants because acute leuke-
mia and 47% congenital or acquired bone marrow failure. Between
autologous transplants 11 patients, 6 high risk neuroblastoma (55%),
Relapsed Hodgkin disease (18%), AML (9%), PNET (9%) and Non
Hodgkin lymphoma (9%). Primary results after two years are care-
fully described. Transplant related mortality is 11.5%, overall sur-
vival and event free survival are 50% and 50% respectively in
a follow up of one year. We conclude that in a pediatric population
is usual have more allogeneic transplants because of non malignant
diseases, the primary results are comparable with those for long
term experience centers given that the isolation rooms, pediatric fa-
cilities, Pediatric Intensive care in situ, and the well designed sup-
portive care strategies.255
THE IMPACT OF ROUTINE RANGE OF MOTION ASSESSMENT ON THE
EARLY IDENTIFICATION OF GRAFT VERSUS HOST DISEASE IN ALLOGE-
NEIC BONE MARROW TRANSPLANT RECIPIENTS
Hente, M.1, Chadakhtzian, A.1, Witte, B.1, Yocco, M.1, Hayashi, R.2,
Shenoy, S.2, Westfall, A.1 1 St. Louis Children’s Hospital, St. Louis,
MO; 2 Washington University, St. Louis, MO
Purpose:To explore the relationship between monthly range of mo-
tion assessment in allogeneic bone marrow transplant (BMT) recip-
ients and how it impacts early identification of graft versus host
disease (GvHD) and improved functional outcomes for this popula-
tion.
Abstract: Acute and chronic GvHD is prevalent in allogeneic BMT
recipients and can lead to debilitating skin and joint issues affecting
quality of life and mobility. As standard of care, these recipients re-
ceive Occupational and Physical Therapy services to combat or pre-
vent sequelae from this debilitating disorder. A recent review of
GvHD and Physical Therapy literature illustrates a lack of early
identification/prediction methods for this disorder. Very few studies
describe specific therapeutic interventions as prophylaxis utilizing
the expertise of Occupational and Physical Therapy personnel.
This institution hopes to change that and devise a method of useful
follow up.
The study population includes allogeneic BMT recipients ages
zero to 18 years old. The control group consists of the past 20 allo-
geneic bone marrow recipients and the experimental group includes
the next 20. Standard goniometry will be the assessment tool utilized
for passive range of motion. A baseline measurement will be obtained
during transplant admission, once a month for the next six months,
followed by every two to three months from month six to 24 on all
participants in the experimental group. The control group will re-
ceive standard goniometry assessment upon the diagnosis of any
GvHD, and/or at one year post transplant or with their next visit if
past one year. Functional outcomes will be measured using the Wee-
FIM, which is an 18-item assessment of what a child actually does.
